{"slug":"eloralintide","seoKey":"eloralintide","inn":"eloralintide","displayName":"Eloralintide","codes":["LY3841136","LY-3841136","AMY-1176","AT53786","LM-232"],"synonyms":["eloralintide","eloralintidum","éloralintide","eloralintida","LY3841136","amylin analogue LY3841136"],"legalClass":"investigational","identifiers":{"cas":"2883634-40-8","pubchemCid":175663130,"unii":"73G3354J8W","inchikey":"RLBIFQNAUXZCQB-UHFFFAOYSA-N","chemblId":"CHEMBL6068462","wikidataQid":"Q141202873","formula":"C201H319N49O65S2","molecularWeight":4526,"sequence":"XCNTATCATG XLAEFLVRSS NNFGPKLPPT EVGSNTY"},"approvals":[{"market":"US","status":"investigational","note":"Not approved; no entry in the drug approval records and no approved labelling on 2026-09-20. The openFDA query for the substance as a generic name returned no match in both the approval and the labelling endpoint. CONTROL QUERY: the identical query for semaglutide in the same endpoint returned entries, so the query works and the negative finding holds. Human use continues under investigational protocols; five phase 3 trials were running on the same day.","source":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:eloralintide"},{"market":"EU","status":"investigational","note":"Not approved; no centralised marketing authorisation and no ATC code assigned, the chemistry database recording an empty classification list and no first approval. The medicines search could not be read out directly on 2026-09-20 because it renders its results in the browser, so neither result rows nor a no-results message were machine-readable. The negative finding therefore rests on the missing authorisation in every register that could be queried and on the phase 3 status.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=eloralintide"},{"market":"DE","status":"investigational","note":"Not approved. Peptides of this class for obesity and type 2 diabetes follow the centralised European route, and without a European authorisation there is no national one either. Use outside an authorised clinical trial or a compassionate use programme is not provided for, and advertising an unauthorised medicine is prohibited. Derived from the European finding on 2026-09-20, not verified against a separate national register.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=eloralintide"},{"market":"UK","status":"investigational","note":"Not approved; no product entry found for the substance on 2026-09-20. The product database renders its results in the browser and returned only a loading placeholder, so the finding rests on the absence of any result together with the missing authorisation worldwide.","source":"https://products.mhra.gov.uk/search/?search=eloralintide"},{"market":"AU","status":"not_approved","note":"Not approved; no indication of an entry in the register of therapeutic goods. The regulator's site could not be reached from the working environment at all on 2026-09-20, every request failing without an HTTP status even with a browser user agent, so no control query was possible either. This finding rests solely on indirect evidence and is the weakest of the seven.","source":"https://www.tga.gov.au/resources/artg"},{"market":"CA","status":"not_approved","note":"Not approved; the drug product database returned an empty array for the active ingredient on 2026-09-20, so there is no product number. CONTROL QUERY: the same endpoint returned several records with product codes and strengths for tirzepatide, so the query works and the negative finding is verified.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=eloralintide"},{"market":"CH","status":"not_approved","note":"Not approved. The regulator's overview of authorised medicines returned HTTP 404 on 2026-09-20 and the product information portal serves only its entry page without JavaScript, so the status could not be verified against a primary document. It is derived from the absence of any authorisation in every register that could be queried.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"phase3","strongestEvidence":"rct_phase2","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT05295940","name":"First study in humans: single and multiple ascending doses (LY3841136)","phase":"Phase 1","n":148,"status":"COMPLETED"},{"nct":"NCT06230523","name":"48-week dose-finding monotherapy trial in adults without type 2 diabetes","phase":"Phase 2","n":263,"status":"COMPLETED"},{"nct":"NCT06345066","name":"Eloralintide in combination with tirzepatide","phase":"Phase 1","n":96,"status":"COMPLETED"},{"nct":"NCT06297616","name":"Multiple doses in Japanese participants, alone and with tirzepatide","phase":"Phase 1","n":128,"status":"COMPLETED"},{"nct":"NCT06916091","name":"Single dose in Chinese participants","phase":"Phase 1","n":30,"status":"COMPLETED"},{"nct":"NCT06916065","name":"Relative bioavailability, alone and with tirzepatide","phase":"Phase 1","n":188,"status":"COMPLETED"},{"nct":"NCT06603571","name":"Eloralintide and tirzepatide, alone or combined, in type 2 diabetes","phase":"Phase 2","n":367,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT07215559","name":"Macupatide and eloralintide, alone or combined, in type 2 diabetes","phase":"Phase 2","n":200,"status":"RECRUITING"},{"nct":"NCT07321886","name":"ENLIGHTEN-1 — obesity or overweight without type 2 diabetes","phase":"Phase 3","n":1980,"status":"RECRUITING"},{"nct":"NCT07282600","name":"ENLIGHTEN-2 — obesity or overweight with type 2 diabetes","phase":"Phase 3","n":1035,"status":"RECRUITING"},{"nct":"NCT07369011","name":"ENLIGHTEN-3 — master protocol, moderate to severe obstructive sleep apnoea","phase":"Phase 3","n":800,"status":"RECRUITING"},{"nct":"NCT07353931","name":"ENLIGHTEN-4 — master protocol, knee osteoarthritis pain","phase":"Phase 3","n":900,"status":"RECRUITING"},{"nct":"NCT07392190","name":"ENLIGHTEN-6 — obesity persisting on weekly incretin treatment","phase":"Phase 3","n":900,"status":"RECRUITING"},{"nct":"NCT07426380","name":"Pharmacokinetics in renal impairment","phase":"Phase 1","n":28,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT07401862","name":"Pharmacokinetics in hepatic impairment","phase":"Phase 1","n":36,"status":"RECRUITING"}],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/175663130","https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068462/","https://www.wikidata.org/wiki/Q141202873"],"lastVerified":"2026-09-20","version":"1.0","published":true,"locale":"en","title":"Eloralintide: what the trials show, status and safety","summary":"Eloralintide is an experimental copy of amylin, a hunger-regulating hormone from the pancreas, given in the trials as a subcutaneous injection once a week. No country has approved it; the phase 3 trials report from 2028. In a 48-week trial in 263 adults, weight fell by 9 to 20 per cent, against 0.4 per cent on placebo. Nausea reached 64 per cent in one group.","updated":"2026-09-20","url":"https://mypep.app/peptides/eloralintide"}